tradingkey.logo

MannKind Corp

MNKD
5.250USD
-0.170-3.14%
Cierre 11/11, 16:00ETCotizaciones retrasadas 15 min
1.61BCap. mercado
55.14P/E TTM

Más Datos de MannKind Corp Compañía

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Información de MannKind Corp

Símbolo de cotizaciónMNKD
Nombre de la empresaMannKind Corp
Fecha de salida a bolsaJul 28, 2004
Director ejecutivoDr. Michael E. Castagna, Pharm.D.
Número de empleados407
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 28
Dirección1 Casper Street
CiudadDANBURY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal06810
Teléfono18186615000
Sitio Webhttps://mannkindcorp.com/
Símbolo de cotizaciónMNKD
Fecha de salida a bolsaJul 28, 2004
Director ejecutivoDr. Michael E. Castagna, Pharm.D.

Ejecutivos de MannKind Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Christine Mundkur, J.D.
Ms. Christine Mundkur, J.D.
Independent Director
Independent Director
27.68K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
24.46K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
-6.09%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
-5.74%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
76.53M
100.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%

Estadísticas de accionistas

Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.68%
The Vanguard Group, Inc.
5.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.28%
Otro
78.34%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.68%
The Vanguard Group, Inc.
5.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.48%
Nitorum Capital, L.P.
2.28%
Otro
78.34%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
23.00%
Investment Advisor/Hedge Fund
17.68%
Hedge Fund
10.68%
Research Firm
3.31%
Individual Investor
1.72%
Bank and Trust
0.62%
Pension Fund
0.32%
Venture Capital
0.03%
Insurance Company
0.03%
Otro
42.62%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
473
171.20M
55.75%
-15.78M
2025Q2
477
184.37M
60.10%
+2.23M
2025Q1
482
184.47M
60.73%
+2.52M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
23.58M
7.69%
+2.13M
+9.93%
Jun 30, 2025
The Vanguard Group, Inc.
18.10M
5.9%
+838.68K
+4.86%
Jun 30, 2025
State Street Investment Management (US)
10.75M
3.5%
+1.28M
+13.47%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.62M
2.48%
+831.48K
+12.25%
Jun 30, 2025
Nitorum Capital, L.P.
7.01M
2.29%
-774.19K
-9.94%
Jun 30, 2025
Two Sigma Investments, LP
5.91M
1.93%
-1.19M
-16.80%
Jun 30, 2025
Avoro Capital Advisors LLC
5.85M
1.91%
-2.90M
-33.14%
Jun 30, 2025
Millennium Management LLC
4.48M
1.46%
-1.34M
-23.03%
Jun 30, 2025
Qube Research & Technologies Ltd
4.07M
1.33%
+825.61K
+25.48%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.05M
1.32%
+528.66K
+15.00%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Invesco Biotechnology & Genome ETF
3.53%
ALPS Medical Breakthroughs ETF
1.01%
Invesco NASDAQ Future Gen 200 ETF
0.57%
VictoryShares Small Cap Free Cash Flow ETF
0.43%
Global X Aging Population ETF
0.31%
SPDR S&P Biotech ETF
0.29%
SPDR S&P Kensho New Economies Composite ETF
0.26%
Timothy Plan US Small Cap Core ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
Ver más
Invesco Biotechnology & Genome ETF
Proporción3.53%
ALPS Medical Breakthroughs ETF
Proporción1.01%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.57%
VictoryShares Small Cap Free Cash Flow ETF
Proporción0.43%
Global X Aging Population ETF
Proporción0.31%
SPDR S&P Biotech ETF
Proporción0.29%
SPDR S&P Kensho New Economies Composite ETF
Proporción0.26%
Timothy Plan US Small Cap Core ETF
Proporción0.22%
ProShares Ultra Nasdaq Biotechnology
Proporción0.17%
Invesco Nasdaq Biotechnology ETF
Proporción0.16%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI